Moderna Stock News

The Nasdaq-100 index tracks the largest 100 non-financial companies on the Nasdaq stock exchange. Although it's not a part of the U.S. stock market's big three indexes ( S&P 500 , Nasdaq Composite, and Dow Jones), the Nasdaq-100 has grown in popularity over the years because of its concentration of tech stocks (almost 60%), many of which have seen their valuations skyrocket in recent years.

Moderna's stock is undervalued, so I maintain a positive outlook with a $97 price target for next year. 3Q24 results show good COVID-19 revenue, cost efficiency, and a significant cash balance, but RSV vaccine sales underperformed. The pipeline includes promising next-gen COVID-19, RSV, flu, CMV, norovirus, and oncology drugs, with substantial revenue potential by 2027.

CAMBRIDGE, MA / ACCESSWIRE / November 25, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: 7th Annual Evercore ISI HealthCONx Conference, on Wednesday, December 4th at 1:20pm ET Piper Sandler 36th Annual Healthcare Conference, on Thursday, December 5th at 10:30am ET A live webcast of each of these presentations will be availab...

Moderna (MRNA) shares surged further Friday, a day after a senior executive made bullish comments at a healthcare conference about the vaccine maker's pipeline and cash position.

Moderna, Inc. (NASDAQ:MRNA ) Jefferies London Healthcare Conference November 21, 2024 9:00 AM ET Company Participants Lavina Talukdar - IR Conference Call Participants Michael Yee - Jefferies Michael Yee Good afternoon everyone. Thank you for joining us on the next session.

Moderna stock remains under pressure with analysts projecting steep losses in the fourth quarter. Is MRNA stock a sell today?

The mRNA (messenger RNA) technology that powered the rapid development of COVID-19 vaccines is now driving a broader revolution in medicine. According to Berenberg, this innovative approach has the potential to transform the treatment of multiple ailments, particularly cancer and infectious diseases.

Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. Department of Health and Human Services.